N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=114 Infant Aphakia Treatment Study (IATS)
Congenital Cataract
Primary: Visual Acuity — 0.80; 0.97 logMAR units — p=0.19
N/A N=110 Infrared Choroidal Reflectance Camera for the Detection of Childhood Cataract
Childhood Cataract
Primary: Results of Red-reflex and Infrared-reflex Tests Compared to Gold Standard — 17; 54; 32; 7 eyes
N/A N=3,785 Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313
Posterior Capsule Opacification
Primary: Percentage of Eyes With Posterior Capsule Opacification Following Implantation of IOL 313 up to 8 Years — 7.9; 4.7; 17.1; 8.2 percentage of eyes
N/A N=390 Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts
Intumescent Cataract
Primary: Percentage of Capsular Tears (Anterior or Posterior) During Surgery — 5.3; 5.3 percentage of capsular tears
Phase 3 N=78 A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement
Unilateral Cataract Extraction · Congenital Cataract
Primary: Intraoperative Pupil Diameter — 0.14; 0.20 millimeters*minutes
Phase 3 N=1,020 Collaborative Italian-American Clinical Trial of Nutritional Supplements and Age-related Cataract (CTNS)
Cataract
Primary: Number of Participants Showing Development or Progression of Age-related Cataract or Undergoing Cataract Surgery During Follow-up — 227; 255 participants — p=0.03
N/A N=80 Quatera 700 vs. Centurion
Cataract
Primary: Central Corneal Thickness — 572.8; 565.6 microns
Phase 2 N=15 Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)
Leber Congenital Amaurosis
Primary: Overall Safety of Adeno-Associated Virus Vector (AAV-OPTIRPE65) - Number of Participants With a Safety Event — 0; 0; 1; 0 Participants
N/A N=369 Prospective Clinical Trial to Evaluate the Safety and Effectiveness of the IOL
Cataract Unilateral · Aphakia
Primary: Best Corrected Distance Visual Acuity — 308 Participants
Phase 2 N=5 CNTF Implants for CNGB3 Achromatopsia
Eye Disease · Achromatopsia
Primary: Number of Adverse Events at Six Months Post-Implantation — 10 Adverse Events
N/A N=35 Enhancement of Emmetropization in Highly Hyperopic Infants
Hyperopia
Primary: Central Cycloplegic Refractive Error With Retinoscopy — 1.6; 1.2; 2.8 Diopters
N/A N=100 Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF
Capsule Opacification · Pseudophakia · Cataract
Primary: Posterior Capsule Opacification (PCO) — 3.0; 1.9 units on a scale (0-10)
N/A N=108 Next Generation Cataract Surgery Study
Cataract
Primary: Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Anterior Segment Surgical Functionality Perform Per the Intended Use as Defined in Protocol Section…
Phase 3 N=60 Study of the Femtosecond Laser System as Compared to Continuous Curvilinear Capsulorhexis for Cataract Surgery
Cataract
Primary: Deviation From Intended Capsulotomy Diameter — 26.8; 339.1 μm
N/A N=120 Microbiological Evaluation of the Ocular Flora Before Cataract Surgery
Disorders of the Eye Following Cataract Surgery
Primary: Positive Culture in Subjects Scheduled for Cataract Surgery — 87 subjects
Phase 3 N=122 One-Piece Hydrophobic Acrylic Intraocular Lens in Subjects Undergoing Cataract Extraction
Aphakia · Cataract
Primary: Visual Acuity — 108 Participants
Phase 2 N=328 Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis
Cystinosis
Primary: Number of Participants With Serious and Non-Serious Adverse Events — 257 participants
Phase 2 N=35 Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
Cytomegalovirus Infection
Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859
N/A N=98 Corrected VA With Long-Term Follow-Up After AcrySof® Intraocular Lens (IOL) Implantation
Pseudophakia
Primary: Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at the Long-Term, Post-Implantation Visit — -0.06; -0.09; -0.07; 0.01 logMAR
Phase 4 N=20 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema
Macular Edema, Cystoid · Vision Disorders · Diabetic Macular Edema
Primary: Change in the Central Macular Thickness — 85.67; -18.22 Microns
N/A N=229 Toric Intraocular Lens Following Cataract Surgery
Cataract · Astigmatism
Primary: Percent Reduction in Absolute Cylinder — 84.975; 46.498 percentage of intended cylinder reduct
N/A N=118 Next Generation Cataract and Vitreoretinal Surgery Study
Vitreoretinal Disease With or Without Cataracts
Primary: Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Using Vitreoretinal or Combined Surgical Functionality Perform Per the Intended Use as Defined in…
N/A N=100 Assessment of Low Energy Lens Fragmentation Cataract Extraction in Patients Undergoing Cataract Surgery
Cataract
Primary: Total Lens Removal Time — 76.0; 80.1 seconds
N/A N=94 Femtosecond Laser Assisted Keratotomies for the Management of Corneal Astigmatism
Astigmatism · Cataract
Primary: Keratometric Correction Index — 0.51 index
N/A N=104 Posterior Capsule Opacification (PCO) Evaluation of the AcrySof SN60AT Lens vs. SN60WF Lens
Cataract
Primary: Posterior Capsule Opacification (PCO) — 11.58; 14.04 Percentage of PCO
N/A N=20 Optimizing the Ocular Surface Prior to Cataract Surgery
Corneal Dystrophy, Epithelial Basement Membrane
Primary: Change in Intraocular Lens Calculation — 1.56; 0.94 D
Phase 1 N=24 Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children
Congenital Nasolacrimal Duct Obstruction
Primary: Change in Physician-rated Scale of NLDO From Baseline to Follow-Up Visit at Week 8 or From Baseline to Time of Treatment Failure, if Earlier. — 7; 10; 1; 1 participants
Phase 4 N=79 Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery
Cystoid Macular Edema
Primary: Central Macular Thickness (Difference in Mean Pre-post Changes by the Two Treatment Groups) — 2.78; 5.6 microns — p=0.7029
Phase 2 N=11 Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene
Leber's Congenital Amaurosis
Primary: Frequency and Severity of Ocular Adverse Events in the Treatment and Contralateral Eyes — 6; 5 Participants